Nina Magnolo, Michael C Cameron, Mona Shahriari, Bob Geng, Brian M Calimlim, Henrique Teixeira, Xiaofei Hu, Yang Yang, Yingyi Liu, Shiyu Zhang, Cristina Sancho Sanchez, Katherine Altman, Richard G Langley
Purpose: Atopic dermatitis (AD) adversely impacts quality of life (QoL). We evaluated the effect of upadacitinib, an oral selective Janus kinase inhibitor approved for moderate-to-severe AD, plus topical corticosteroids (+TCS) on patient-reported outcomes (PROs) over 52 weeks. Materials and methods: In the phase 3 AD Up study (NCT03568318), adults and adolescents with moderate-to-severe AD were randomized 1:1:1 to once-daily upadacitinib 15 mg, 30 mg, or placebo + TCS. Itch, skin pain/symptoms, sleep, QoL, daily activities, emotional state, mental health, and patient impressions of disease severity/improvement/treatment satisfaction were assessed...
December 2024: Journal of Dermatological Treatment